RICTOR Amplification in Lung Cancer Patients
Haiying Cheng, MD, medical oncologist, Montefiore Einstein Center for Cancer Car, assistant professor, Department of Medicine (Oncology), Albert Einstein College of Medicine, discuses RICTOR amplification in patients with lung cancer.
Haiying Cheng, MD, medical oncologist, Montefiore Einstein Center for Cancer Car, assistant professor, Department of Medicine (Oncology), Albert Einstein College of Medicine, discuses RICTOR amplification in patients with lung cancer.
Clinical Pearls:
- RICTORwas first identified in 2004 and is a key component of the mTOR protein complex.
- After examining two databases in which patients with lung cancer had undergone next-generation sequencing, it was found that about 8% of patients hadRICTORamplification.
- Several compounds were tested but it was found that mTOR1/2 inhibitors are the most active against the amplification.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
